Diaceutics has introduced a new laboratory network - Labceutics - to provide services to the personalized medicine (PM) market in Europe.

Labceutics provides pharma firms with value enhancing laboratory networks and services required to provide companion diagnostic testing for PM.

Diaceutics CEO Peter Keeling said pharmaceutical companies and diagnostic firms need to collaborate more closely with physicians during the theranostic development process, so that when the test is on the market, the endorsement of fellow physicians will aid in its greater adoption.

Hospital General Universitario Gregorio Maranon medical oncology chief Miguel Martin said Labceutics’ partnerships will have benefits for physicians, clinical research programs, and most of all, patients.